

PB 63 of 2021

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 6)

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.

Dated 29 June 2021

NIKOLAI TSYGANOV

Assistant Secretary (Acting)
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health

Contents

1	Name	
2	Commencement	1
3	Authority	1
4	Schedule	1
Schedule	1—Amendments	2
λ	ational Health (Continued Dispensing - Emergency Measures) Determination 2020	2

1 Name

- (1) This instrument is the *National Health (Continued Dispensing Emergency Measures) Amendment Determination 2021 (No. 6).*
- (2) This instrument may also be cited as PB 63 of 2021.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information					
Column 1	Column 2	Column 3			
Provisions	Commencement	Date/Details			
1. The whole of this instrument	1 July 2021.				

Note:

This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 89A(3) of the *National Health Act* 1953

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

[1] Scl	thedule 1, entry for Captopril	
	Tablet 25 mg	Oral
	Tablet 50 mg	Oral
[2] Scl	hedule 1, entry for Guselkumab	
inse	ert as first entry:	
	Injection 100 mg in 1 mL single use pre-filled pen	Injection
	de adoda Allaffan andere fan Heidnam ande ana hadda fanna And Heile (d. 1919). Gelek e	
	thedule 1, after entry for Hydromorphone in the form Oral liquid containing hydrer: Oral solution containing hydromorphone hydrochloride 1 mg per mL, 473 mL	dromorphone hydrochloride 1 mg per mL
inse	Oral solution containing hydromorphone hydrochloride 1 mg per mL, 473 mL chedule 1, after entry for Imipramine in the form Tablet containing imipramine	Oral
inse	Oral solution containing hydromorphone hydrochloride 1 mg per mL, 473 mL chedule 1, after entry for Imipramine in the form Tablet containing imipramine	Oral
inse	Oral solution containing hydromorphone hydrochloride 1 mg per mL, 473 mL chedule 1, after entry for Imipramine in the form Tablet containing imipramine left:	Oral hydrochloride 10 mg
inse [4] Scl inse	Oral solution containing hydromorphone hydrochloride 1 mg per mL, 473 mL chedule 1, after entry for Imipramine in the form Tablet containing imipramine left: Tablet containing imipramine hydrochloride 10 mg USP	Oral hydrochloride 10 mg
inse [4] Scl inse	Oral solution containing hydromorphone hydrochloride 1 mg per mL, 473 mL chedule 1, after entry for Imipramine in the form Tablet containing imipramine left: Tablet containing imipramine hydrochloride 10 mg USP chedule 1, after entry for Indometacin in the form Suppository 100 mg	Oral hydrochloride 10 mg

[7]	Schedule 1, after entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less t 25,000 BP units of lipase activity				
	insert:				
	Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase Oral activity				
[8]	Schedule 1, entry for Progesterone				
	insert as first entry:				
	Capsule 200 mg Vaginal				
[9]	Schedule 1, after entry for Tofacitinib in the form Tablet 5 mg				
	insert:				
	Tablet 10 mg Oral				